{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:38:46Z","timestamp":1794299926007,"version":"4.9.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.14283\/jpad.2022.84","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T02:40:57Z","timestamp":1664937657000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients"],"prefix":"10.1016","volume":"10","author":[{"given":"Cheng","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Liow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maccecchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2022.84_bib1","unstructured":"The Challenge of Neurodegenerative Diseases, in Harvard NeuroDiscovery Center."},{"key":"10.14283\/jpad.2022.84_bib2","article-title":"How early can we diagnose Alzheimer disease","author":"Peterson","year":"2017","journal-title":"Neurology"},{"key":"10.14283\/jpad.2022.84_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer's disease: causes and treatment","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"10.14283\/jpad.2022.84_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/ana.21706","article-title":"The Neuropathology of Probable Alzheimer","author":"Schneider","year":"2009","journal-title":"Ann Neurol"},{"key":"10.14283\/jpad.2022.84_bib5","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-007-0261-2","article-title":"Comorbidit of TDP-43 proteinopathy in Lewy boday related diseases","author":"Nakashima-Yasuda","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.14283\/jpad.2022.84_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-018-9100-8","article-title":"Amyloid-\u03b2 and Parkinson's disease","author":"Lim","year":"2019","journal-title":"J Neurol"},{"key":"10.14283\/jpad.2022.84_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2013.12.018","article-title":"Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations","author":"Alami","year":"2014","journal-title":"Neuron"},{"key":"10.14283\/jpad.2022.84_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw9997","article-title":"H.E., axonal transport: driving synaptic function","author":"Guedes-Dias","year":"2019","journal-title":"science"},{"key":"10.14283\/jpad.2022.84_bib9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.1074069","article-title":"Alzheimer's disease is a synaptic failure","author":"Selkoe","year":"2002","journal-title":"Science"},{"key":"10.14283\/jpad.2022.84_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-7091-0932-8_24","article-title":"Synaptic dysfunction in Parkinson's disease","author":"Picconi","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"10.14283\/jpad.2022.84_bib11","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1083\/jcb.200108057","article-title":"Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress","author":"Stamer","year":"2002","journal-title":"J Cell Biol"},{"key":"10.14283\/jpad.2022.84_bib12","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.5427-08.2009","article-title":"Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy","author":"Chung","year":"2009","journal-title":"J Neurosci"},{"key":"10.14283\/jpad.2022.84_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13122109","article-title":"Posiphen Reduces the Levels of Huntingtin Protein through translation suppression","author":"Chen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.14283\/jpad.2022.84_bib14","doi-asserted-by":"crossref","unstructured":"Rogers JT, M.S., Cantuti-Castelvetri I, Smith DH, Huang X, Bandyopadhyay S, Cahill CM, Maccecchini ML, Lahiri DK, Greig NH., The alpha-synuclein 5' untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and posiphen. 2011.","DOI":"10.1007\/s00702-010-0513-5"},{"key":"10.14283\/jpad.2022.84_bib15","doi-asserted-by":"crossref","unstructured":"Cho HH, C.C., Vanderburg CR, Scherzer CR, Wang B, Huang X, Rogers JT., Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. 2010.","DOI":"10.1074\/jbc.M110.149161"},{"key":"10.14283\/jpad.2022.84_bib16","article-title":"Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model","author":"Chen","year":"2020","journal-title":"Alzheimer's & dementia"},{"key":"10.14283\/jpad.2022.84_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.trci.2017.12.001","article-title":"Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP\/PS1 mouse","author":"Teich","year":"2018","journal-title":"Alzheimer's & dementia"},{"key":"10.14283\/jpad.2022.84_bib18","first-page":"1","article-title":"Translational inhibition of \u03b1-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice","author":"Kuo","year":"2019","journal-title":"Am J Neurodegener Dis"},{"key":"10.14283\/jpad.2022.84_bib19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0963689718766328","article-title":"Sequential combined Treatment of Pifithrin-a and posiphen enhances neurogenesis and functional recovery after stroke","author":"Turcato","year":"2018","journal-title":"Cell Transplantation"},{"key":"10.14283\/jpad.2022.84_bib20","unstructured":"Hatami A, M.K., Sutton R, Ghavim S, Dutta G, Maccecchini M, Chesselet MF, Posiphen reverses behavioral deficits and neuropathology in a rat model of mild traumatic brain injury. 2016, Military Health System Research Symposium."},{"key":"10.14283\/jpad.2022.84_bib21","article-title":"Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-b peptide and tau levels: target engagement, tolerability and pharmacokinetics in humans","author":"Maccecchini","year":"2012","journal-title":"JNNP"},{"key":"10.14283\/jpad.2022.84_bib22","doi-asserted-by":"crossref","unstructured":"Goborm J, P.L., Rosa-Neto P, Vyhnalek M, Gauthier S, Zetterberg H, Sheardova K, Hort J, Blennow K, Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. 2021.","DOI":"10.1515\/cclm-2021-0651"},{"key":"10.14283\/jpad.2022.84_bib23","doi-asserted-by":"crossref","unstructured":"Ashton N, S.-C.M., Heslegrave A, Blennow K, Hodges A, Zetterberg H, Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. 2019.","DOI":"10.1186\/s13195-019-0545-5"},{"key":"10.14283\/jpad.2022.84_bib24","doi-asserted-by":"crossref","unstructured":"Rosengren L, W.C., Hagberg L, A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. 1994.","DOI":"10.1016\/0165-0270(94)90011-6"},{"key":"10.14283\/jpad.2022.84_bib25","series-title":"Basid Pharmacokinetics and Pharmacodynamics","first-page":"102","author":"Rosenbaum","year":"2016"},{"key":"10.14283\/jpad.2022.84_bib26","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-170991","article-title":"The Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. A narrative review","author":"Kueper","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.14283\/jpad.2022.84_bib27","first-page":"759","article-title":"Speed and memory in the WAIS-III digital symbol-coding subtest across the adult lifespan","author":"Joy","year":"2004","journal-title":"neuropsychology"},{"key":"10.14283\/jpad.2022.84_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242233","article-title":"The number symbol coding task: a brief measure of executive function to detect dementia and cognitive impairment","author":"Galvin","year":"2020","journal-title":"Plos One"},{"key":"10.14283\/jpad.2022.84_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-020-00657-8","article-title":"Association of glial and neuronal degeneration markers with Alzheimer's disease cerebrospinal fluid profile and cognitive functions","author":"Teitsdottir","year":"2020","journal-title":"Alzheimer's research & therapy"},{"key":"10.14283\/jpad.2022.84_bib30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","article-title":"TREM2-a key player in microglial biology and Alzheimer disease","author":"Ulland","year":"2018","journal-title":"Nature reviews neurology"},{"key":"10.14283\/jpad.2022.84_bib31","first-page":"906","article-title":"YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer's disease. Curr","author":"Muszynski","year":"2017","journal-title":"Neuropharmacol"},{"key":"10.14283\/jpad.2022.84_bib32","article-title":"Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy","author":"Wu","year":"2018","journal-title":"Cell Reports"},{"key":"10.14283\/jpad.2022.84_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-018-0404-9","article-title":"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease","author":"Lewczuk","year":"2018","journal-title":"Alzheimer's research & therapy"},{"key":"10.14283\/jpad.2022.84_bib34","article-title":"Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.14283\/jpad.2022.84_bib35","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010084","article-title":"NFL as a biomarker for neurodegeneration and survival in Parkinson disease","author":"Backstrom","year":"2020","journal-title":"Neurology"},{"key":"10.14283\/jpad.2022.84_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2012.05.010","article-title":"Mammalian iron metabolism and its control by iron regulatory proteins","author":"Anderson","year":"2012","journal-title":"Biochem Biophys Acta"},{"key":"10.14283\/jpad.2022.84_bib37","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M110.149161","article-title":"Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein 1","author":"Cho","year":"2010","journal-title":"J Biol Chem"},{"key":"10.14283\/jpad.2022.84_bib38","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-179944","article-title":"Iron and Alzheimer's disease: an update on emerging mechanisms","author":"Lane","year":"2018","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.14283\/jpad.2022.84_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065978","article-title":"Novel 5' Untranslatied region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrom and alzheimer's disease","author":"Bandyopadhay","year":"2013","journal-title":"Plos One"},{"key":"10.14283\/jpad.2022.84_bib40","article-title":"Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights from Althernative Hypotheses","author":"Chen","year":"2019","journal-title":"Frontier in Neuroscience"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724002462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724002462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:10:57Z","timestamp":1737339057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724002462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2274580724002462"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2022.84","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2022.84","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}